Phase 2Recruiting
Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia
A Phase II Study Evaluating the Efficacy of Ruxolitinib in Patients With T-Cell Large Granular Lymphocytic Leukemia (T-LGLL)
- Sponsor
- Jonathan Brammer (Academic or other)
- Enrollment
- 30 planned
- Conditions
- T-Cell Large Granular Lymphocyte Leukemia
- Interventions
- Ruxolitinib
- Ages
- adults, older adults
- Registry
- NCT05592015
Full record on ClinicalTrials.gov
From the registry
This phase II trial tests whether ruxolitinib works to shrink tumors in patients with T-cell large granular lymphocyte leukemia. Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Primary outcomes
- Overall response rate (ORR)
History
Primary completion expected
Last registry update
Started
Registered